Article
Clinical Updates in Blood and Marrow Transplantation in Multiple Myeloma
The process of hematopoietic stem cell transplantation (HSCT) is well defined, yet debate remains surrounding the role and timing of HSCT in patients with multiple myeloma (MM). Since the 1980s, survival advances have been made with the use of newer agents by recognizing the role of transplantation, identifying the anticipated side effects at each phase, and improving supportive care strategies. Data support transplantation as part of the treatment strategy, but the optimal induction regimen and timing of transplantation have yet to be defined. The general consensus is that eligible patients should undergo autologous HSCT at some point in the treatment spectrum, preferably earlier rather than later in the disease. Allogeneic transplantation is only recommended in the context of a clinical trial and in patients with high-risk disease. The transplantation process can be overwhelming for patients and caregivers. Nurses play a key role in improving outcomes by caring for patients and families throughout the transplantation experience and, therefore, need to be knowledgeable about the process. This article is intended to expand discussion on the role of nurses in assisting patients and families undergoing transplantation to include an overview of the acute care phase of the transplantation process.
Jump to a section
References
Adel, N. G., Duck, E., Collum, K., Mccullagh, E., Reich, L., Landau, H., … Hassoun, H. (2011). Cost analysis of using plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients treated at Memorial Sloan-Kettering Cancer Center [Abstract 3537]. ASH Annual Meeting Abstracts, 118, 4059.
Amgen Inc. (2013). Neupogen® (filgrastim) [Package insert]. Retrieved from http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf
Antin, J. H., & Yolin Raley, D. (2009). Stem cell sources. In J. H. Antin & D. Yolin Raley (Eds.), Manual of stem cell and bone marrow transplantation (pp. 9-15). New York, NY: Cambridge University Press.
Bensinger, W. I. (2009). Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia, 23, 442-448.
Bevans, M., Tierney, D. K., Bruch, C., Burgunder, M., Castro, K., Ford, R., … Schmit-Pokorny, K. (2009). Hematopoietic stem cell transplantation nursing: A practice variation study [Online exclusive]. Oncology Nursing Forum, 36, E317-E325. doi:10.1188/09.ONF.E317-E325
Blombery, P., Prince, H. M., Worth, L. J., Main, J., Yang, M., Wood, E. M., & Westerman, D. A. (2011). Prophylactic intravenous immunoglobulin during autologous haematopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Annals of Hematology, 90, 1167-1172.doi:10.1007/s00277-011-1275-3
Burkhart, M. C., Wade, J., & Lesperance, V. (2013). Evidence-based guideline recommendations: Post-hematopoietic stem cell transplantation [Online exclusive]. Clinical Journal of Oncology Nursing, 17, E63-E67. doi:10.1188/13.CJON.E63-E67
Calandra, G., McCarty, J., McGuirk, J., Tricot, G., Crocker, S. A., Badel, K., … Bridger, G. (2008). AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplantation, 41, 331-338. doi:10.1038/sj.bmt.1705908
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., … Lonial, S. (2011). International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 117, 6063-6073. doi:10.1182/blood-2011-02-297325
Chanan-Khan, A. A., & Giralt, S. (2010). Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal of Clinical Oncology, 28, 2612-2624. doi:10.1200/JCO.2009.25.4520
Cooke, L., Grant, M., & Gemmill, R. (2012). Discharge needs of allogeneic transplantation recipients [Online exclusive]. Clinical Journal of Oncology Nursing, 16, E142-E149. doi:10.1188/12.CJON.E142-E149
DiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N., Stiff, P. J., Kaufman, J. L., … Calandra, G. (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 5720-5726.
DiPersio, J. F., Uy, G. L., Yasothan, U., & Kirkpatrick, P. (2009). Plerixafor. Nature Reviews. Drug Discovery, 8, 105-107.
Durie, B. G., Harousseau, J. L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., … Rajkumar, S. V. (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
El-Cheikh, J., Crocchiolo, R., Furst, S., Stoppa, A. M., Ladaique, P., Faucher, C., … Blaise, D. (2013). Long-term outcome after allogeneic stem cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. American Journal of Hematology, 88, 370-374. doi:10.1002/ajh.23412
Flomenberg, N., Devine, S. M., DiPersio, J. F., Liesveld, J. L., McCarty, J. M., Rowley, S. D., … Calandra, G. (2005). The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 106, 1867-1874.
Genzyme Corporation. (2010). Mozobil® (plerixafor injection) [Package insert]. Retrieved from http://www.mozobil.com/document/Package_Insert.pdf
Gertz, M. A., Wolf, R. C., Micallef, I. N., & Gastineau, D. A. (2010). Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplantation, 45, 1396-1403. doi:10.1038/bmt.2009.370
Giralt, S. (2012). Stem cell transplantation for multiple myeloma: Current and future status. Hematology, 17(Suppl. 1), S117-S120.
Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., … Durie, B. G. (2009). International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 23, 1904-1912. doi:10.1038/leu.2009.127
Gopal, A. K., Harami, M., Mayor, J., Macebeo, M., Linenberger, M., Bensinger, W. I., & Holmberg, L. (2012). The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. Journal of Clinical Apheresis, 27(2), 81-77. doi:10.1002/jca.21206
Harvey, R. D., Lonial, S., Renfroe, H., Sinha, R., Flowers, C. R., Lechowicz, M. J., … Kaufman, J. L. (2011). Temporal changes in plerixafor administration do not impact hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial [Abstract 2988]. Retrieved from http://ash.confex.com/ash/2011/webprogram/Paper35916.html
Hesketh, P. J., Batchelor, D., Golant, M., Lyman, G. H., Rhodes, N., & Yardley, D. (2004). Chemotherapy-induced alopecia: Psychosocial impact and therapeutic approaches. Supportive Care in Cancer, 12, 543-554.
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., … Vij, R. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801-1809. doi:10.1182/blood-2012-04-422683
Koreth, J., Stevenson, K. E., Kim, H. T., McDonough, S. M., Bindra, B., Armand, P., … Alyea, E. P., 3rd. (2012). Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. Journal of Clinical Oncology, 30, 3202-3208. doi:10.1200/JCO.2012.42.0984
Kumar, S. (2009). Stem cell transplantation for multiple myeloma. Current Opinion in Oncology, 21, 162-170. doi:10.1097/CCO.0b013e328324bc04
Kurtin, S., Lilleby, K., & Spong, J. (2013). Caregivers of multiple myeloma survivors. Clinical Journal of Oncology Nursing, 17(Suppl., 2), 25-32.
Laffan, A., & Biedrzycki, B. (2006). Immune reconstitution: The foundation for safe living after an allogeneic hematopoietic stem cell transplantation. Clinical Journal of Oncology Nursing, 10, 787-794. doi:10.1188/06.CJON.787-794
Lara, A. R., & Schwartz, M. I. (2010). Diffuse alveolar hemorrhage. Chest, 137, 1164-1171. doi:10.1378/chest.08-2084
Lilleby, K., Garcia, P., Gooley, T., McDonnell, P., Taber, R., Holmberg, L., … Bensinger, W. (2006). A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 37, 1031-1035. doi:10.1038/sj.bmt.1705384
Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., San Miguel, J., Pérez-Simon, J. A., … Bensinger, W. (2010). International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28, 4521-4530. doi:10.1200/JCO.2010.29.7929
Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., … Tichelli, A. (2012). Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplantation, 47, 337-341. doi:10.1038/bmt.2012.5
Majhail, N. S., & Rizzo, J. D. (2013). Surviving the cure: Long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplantation, 48, 1145-1151. doi:10.1038/bmt.2012.258
Martin, P. J., Schoch, G., Fisher, L., Byers, V., Anasetti, C., Appelbaum, F. R., … Sanders, J. E. (1990). A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood, 76, 1464-1472.
Mattson, M. R. (2007). Graft-versus-host disease: Review and nursing implications. Clinical Journal of Oncology Nursing, 11, 325-328. doi:10.1188/07.CJON.325-328
Micallef, I. N., Sinha, S., Gastineau, D. A., Wolf, R., Inwards, D. J., Gertz, M. A., … Kumar, S. (2013). Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biology of Blood and Marrow Transplantation, 19, 87-93. doi:10.1016/j.bbmt.2012.08.010
Miceli, T., Lilleby, K., Noonan, K., Kurtin, S., Faiman, B., & Mangan, P. A. (2013). Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: An overview for nurses in community practice. Clinical Journal of Oncology Nursing, 17(Suppl., 2), 13-24.
Moreau, P., Facon, T., Attal, M., Hulin, C., Michallet, M., Maloisel, F., … Harousseau, J. L. (2002). Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood, 99, 731-735. doi:10.1182/blood.V99.3.731
National Cancer Institute. (2013). FDA approval for plerixafor. Retrieved from http://www.cancer.gov/cancertopics/druginfo/fda-plerixafor
Pallera, A. M., & Schwartzberg, L. S. (2004). Managing the toxicity of hematopoietic stem cell transplant. Journal of Supportive Oncology, 2, 223-237.
Palumbo, A., Bladé, J., Boccadoro, M., Palladino, C., Davies, F., Dimopoulos, M., … San Miguel, J. (2012). How to manage neutropenia in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 12(1), 5-11. doi:10.1016/j.clml.2011.11.001
Pasquini, M. C., & Wang, Z. (2011). Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2011. Retrieved from http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx
Potter, P., Eisenberg, S., Cain, K. C., & Berry, D. L. (2011). Orange interventions for symptoms associated with dimethyl sulfoxide during stem cell reinfusions: A feasibility study. Cancer Nursing, 34, 361-368. doi:10.1097/NCC.0b013e31820641a5
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., … Anderson, K. C. (2010). Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679-686. doi:10.1182/blood-2010-02-268862
Rodriguez, A. L. (2010). Management and evaluation of patients receiving high-dose chemotherapy with stem cell transplantation. In J. D. Tariman (Ed.), Multiple myeloma: A textbook for nurses (pp. 155-172), Pittsburgh PA: Oncology Nursing Society.
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., … Bladé, J. (2012). Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood, 120, 1589-1596.
Russell, N., Douglas, K., Ho, A. D., Mohty, M., Carlson, K., Ossenkoppele, G. J., … Chabannon, C. (2013). Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: Results of the prospective PREDICT trial. Haematologica, 98, 172-178. doi:10.3324/haematol.2012.071456
Savani, B. N., Griffith, M. L., Jagasia, S., & Lee, S. J. (2011). How I treat late effects in adults after allogeneic stem cell transplantation. Blood, 117, 3002-3007. doi:10.1182/blood-2010-10-263095
Solomon, S. R., Matthews, R. H., Barreras, A. M., Bashey, A., Manion, K. L., McNutt, K., … Holland, H. K. (2010). Outpatient myeloablative allo-SCT: A comprehensive approach yields decreased hospital utilization and low TRM. Bone Marrow Transplantation, 45, 468-475. doi:10.1038/bmt.2009.234
Sorror, M. L. (2010). Comorbidities and hematopoietic cell transplantation outcomes. Hematology, 2010, 237-246. doi:10.1182/asheducation-2010.1.237
Subramanian, A. K. (2011). Antimicrobial prophylaxis regimens following transplantation. Current Opinion in Infectious Diseases, 24, 344-349. doi:10.1097/QCO.0b013e328348b379
Sung, A. D., & Chao, N. J. (2013). Concise review: Acute graft-versus-host disease: Immunobiology, prevention, and treatment. Stem Cells Translational Medicine, 2(1), 25-32. doi:10.5966/sctm.2012-0115
Talamo, G., Rakszawski, K. L., Rybka, W. B., Dolloff, N. G., Malysz, J., Berno, T., & Zangari, M. (2012). Effect of time to infusion of autologous stem cells (24 versus 48 hours) after high-dose melphalan in patients with multiple myeloma. European Journal of Haemoatology, 89, 145-150. doi:10.1111/j.1600-0609.2012.01795.x
Thomas, A., Mailankody, S., Korde, N., Kristinsson, S. Y., Turesson, I., & Landgren, O. (2012). Second malignancies after multiple myeloma: From 1960s to 2010s. Blood, 119, 2731-2737.
Tuncer, H. H., Rana, N., Milani, C., Darko, A., & Al-Homsi, S. A. (2012). Gastrointestinal and hepatic complication of hematopoietic stem cell transplantation. World Journal of Gastroenterology, 18, 1851-1860. doi:10.3748/wjg.v18.i16.1851
Versluys, A. B., Rossen, J. W., van Ewijk, B., Schuurman, R., Bierings, M. B., & Boelens, J. J. (2010). Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes. Biology of Blood and Marrow Transplantation, 16, 782-791. doi:10.1016/j.bbmt.2009.12.534
Weinstock, D. M., Conlon, M., Iovino, C., Aubrey, T., Gudiol, C., Riedel, E., … Zuccotti, G. (2007). Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation, 13, 615-621.
Williams, S. F., Zimmerman, T., Grad, G., & Mick, R. (1993). Source of stem cell rescue: Bone marrow versus peripheral blood progenitors. Journal of Hematotherapy, 2, 521-523.